Agency's backing for Sinovac jab seen swelling COVAX supplies
The World Health Organization approved on Tuesday a COVID-19 vaccine from Chinese drugmaker Sinovac Biotech for emergency use, a decision that boosts confidence in the global fight against COVID-19, officials said.
Sinovac's vaccine, called Corona-Vac, is the second China-made COVID-19 jab to gain authorization from the world health body, after a separate formulation from drug company Sinopharm was validated in early May.
The Sinovac vaccine is already in use in many nations whose own health authorities have granted approval for the jab. The recent move by the WHO means the jab may now be used as part of the international COVAX project, which oversees the equitable distribution of vaccines around the globe, especially in developing regions.
WHO officials stressed the important role that Chinese vaccines are set to play. China is manufacturing the Sinovac and Sinopharm vaccines in large quantities, and they can be stored at normal refrigeration temperature for extended periods, making them ideal for distribution in areas that lack sufficient cold-chain infrastructure.
"The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe," said Mariangela Simao, who is the WHO assistant director-general for Access to Health Products.
"We urge manufacturers to participate in the COVAX facility, share their know-how and data and contribute to bringing the pandemic under control."
The approval has also been lauded by officials from the Philippines and Chile. On Wednesday, Philippine presidential spokesman Harry Roque said in a statement that the approval will boost the vaccine confidence among Filipinos. The country approved the vaccine for emergency use in February.
In South America, Chile's Deputy Health Minister Paula Daza said: "The fact that the WHO approves a vaccine such as Sinovac's allows us to offer more confidence worldwide in a vaccine that we know is very effective."
Severe delays
Health experts have warned that distribution of Chinese vaccines under COVAX cannot come soon enough, as the project has been hit by severe delays to supply.
"Sinovac could have quite a big impact because it can be stored closer to room temperature, so you can use it in remote regions of the world quite easily," Caroline Casey, lead COVID-19 analyst at science analytics company Airfinity, said.
COVAX had hoped to ship 252 million COVID-19 vaccines in the first half of this year, although as of Monday, just 77 million shots have been distributed.
The project is heavily reliant on vaccines manufactured in India, which imposed an export ban earlier this year in order to combat severe domestic outbreaks, leading to a shortfall in supply.
On Tuesday, the WHO said efficacy results for the Sinovac jab showed the vaccine prevented symptomatic disease in 51 percent of those vaccinated, and prevented severe COVID-19 and hospitalization in 100 percent of the studied population.
Real-world data
Real-world data shows that efficacy in preventing symptomatic disease may be higher than trials suggest.
Last month, Indonesia's health ministry said the vaccine showed 94 percent efficacy in preventing symptomatic infection in 120,000 vaccinated healthcare workers.
On advice from its Strategic Advisory Group of Experts on Immunization, the WHO recommended use of the Sinovac vaccine in people aged 18 and older, in a two-dose schedule, with a spacing of two-to-four weeks.
While few adults over the age of 60 years old were involved in late-stage clinical trials for the Sinovac vaccine, the WHO said it is not recommending an upper age limit for the vaccine.
This is because the vaccine is already in use in many nations, and data from national health authorities suggests the vaccine is likely to have a protective effect in older people.
Sinovac said that, as of late last month, over 430 million doses had already been administered in China and abroad.
Along with the Sinovac and Sinopharm jabs, the WHO has so far given emergency approval to vaccines from Pfizer, Moderna, Astra-Zeneca, and Johnson &Johnson. Clinical trial data has been submitted for a third Chinese vaccine, from CanSino Biologics.
Pakistan rolls out locally made CanSino shot
Pakistan launched local production of a COVID-19 vaccine from Chinese drugmaker CanSino Biologics at a ceremony in Islamabad on Tuesday.
Addressing the launching ceremony for the vaccine named PakVac, Faisal Sultan, the special assistant to the prime minister on health, hailed the step as a milestone for the country. Local production will support Pakistan's battle against COVID-19 by leading the country toward vaccine self-sufficiency.
Sultan told the gathering at the National Institute of Health that China is a true friend that always extends a helping hand to Pakistan in tough times.
The cooperation between the two countries in fighting COVID-19, including vaccine cooperation, has set a good example for other countries, Sultan said.
Pakistani Minister for Planning, Development and Special Initiatives Asad Umar, who also heads the National Command and Operation Center, shared the results of a locally conducted survey at the ceremony. The poll indicated that Chinese vaccines, including CanSino's, are the preferred ones among Pakistanis due to their superior quality and effective results.
Chinese Ambassador to Pakistan Nong Rong said the vaccine cooperation between China and Pakistan not only effectively contributes to Pakistan's efforts in fighting COVID-19 by reducing its dependence on vaccine imports but also adds to the efforts of building a global community of health for all.
With technological support from CanSino, the National Institute of Health recently packed over 120,000 doses of the single-dose CanSino vaccine using a bulk vaccine purchased from China. It was the first time that a COVID-19 vaccine has been produced in the South Asian country.
